Abstract
Acute lymphoblastic leukemia (ALL) includes heterogeneous clinical leukemic syndromes which differ in clinical presentation, immunophenotype, cytogenetics, and clinical outcome. Recognition of this heterogeneity has allowed definition of curative therapy for more than 50% of patients with ALL, especially in children. Despite these scientific and clinical advances, certain patient subgroups at presentation and most after clinical relapse have a poor prognosis and thus have been considered candidates for therapy with bone marrow transplantation (BMT). Since 1982, at the University of Minnesota, we have undertaken a series of consecutive parallel trials of bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia using histocompatible sibling donor marrow when available and ex vivo purged autologous re-mission bone marrow for patients lacking an available matched donor [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brochstein JA, Kernan NA, Groshen S, Cirrincione C, Shank B, Emanuel D, Laver J, O’Reilly RJ (1987) Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in acute leukemia. N Engl J Med 26: 1618–1624
Coccia PF, Strandjord SE, Warkentin PI, Cheung NV, Gordon EM, Novak LJ, Shina DC, Herzig RH (1988) High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 71: 888 - 893
Kersey JH, Weisdorf D, Nesbit ME, LeBien TW, Woods WG, McGlave PB, Kim T, Vallera DA, Goldman Al, Bostrom B, Hurd D, Ramsay NKC (1987) Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 317: 461–467
LeBien TW, Anderson JM, Vallera DA, Uckun FM (1985) Increased efficacy in selective elemination of leukemic cell line clono-genic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamide (ASTA Z 7557). Leuk Res 10: 139–143
Ramsay NKC, Kersey JH, Robinson LL et al. (1982) A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 306: 392–397
Ramsay N, LeBien T, Nesbit M et al. (1985) Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 66: 508–513
Uckun FM, Stong RC, Youle RJ, Vallera DA (1985) Combined ex vivo treatment with immunotoxins and mafosfamide: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. J Immunol 134: 3504–3515
Weisdorf D, Nesbit ME, Ramsay NKC et al. (1987) Allogeneic bone marrow transplanta¬tion for acute lymphoblastic leukemia in remis¬sion: prolonged survival associated with acute graft-versus-host disease. J Clin Oncol 5:1348- 1355
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Weisdorf, D. et al. (1990). Allogeneic and Autologous Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_123
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_123
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive